Daily doses of peanuts tackle allergic reactions in adults
The first clinical trial to test whether adults allergic to peanuts can be desensitised has shown great success with two thirds of the cohort consuming the equivalent of… read more.
The first clinical trial to test whether adults allergic to peanuts can be desensitised has shown great success with two thirds of the cohort consuming the equivalent of… read more.
Marking European Immunization Week (EIW) 2025, the European Centre for Disease Prevention and Control (ECDC) highlights the risks of suboptimal vaccination coverage in Europe and publishes a set… read more.
A multi-state study reveals that many high-risk adults diagnosed with influenza (flu) in emergency departments and urgent care centers are not receiving timely antiviral treatment. Researchers found that… read more.
Pfizer announced that the FDA accepted for review a Biologics License Application (BLA) for MenABCWY, its investigational pentavalent meningococcal vaccine candidate. Pfizer submitted MenABCWY for the prevention of… read more.
GSK plc announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend use of Penmenvy (Meningococcal Groups… read more.
Valneva SE announced that the Brazilian Health Regulatory Agency (ANVISA) approved Ixchiq vacccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of… read more.
The FDA approved neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), in adult and pediatric patients who… read more.
PDS Biotechnology Corporation, a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that preclinical immune response data with a novel… read more.
The first asthma patient has commenced treatment with Relovair (fluticasone furoate/vilanterol trifenatate) in an asthma exacerbation study, marking the start of the Phase III clinical development programme with… read more.
A review published in The Laryngoscope indicates that climate change’s effects on pollen seasons and concentrations are contributing to increasing rates of allergic rhinitis, or hay fever. When investigators assessed… read more.
The FDA announced the approval of Omlyclo (omalizumab-igec) as the first biosimilar to reference Xolair (omalizumab). The biosimilar was also approved with interchangeability status and is the first… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Deqsiga, intended for replacement therapy in people… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.